F ollowing encounter with cognate antigen, naive B cells proliferate and differentiate into antibody-secreting cells (ASCs). Two types of ASCs develop during B cell responses: short-lived plasmablasts and long-lived plasma cells. Plasmablasts are generated early during the B cell response and produce lowaffinity antibody against antigen 1 . B cells entering the germinal centers of secondary lymphoid follicles differentiate into plasma cells 2 . Plasma cells are post-mitotic cells, representing the end stage of the B cell differentiation program, and soon after their development home to the bone marrow and reside within specialized niches. High-affinity antibodies secreted by plasma cells play a critical role in the neutralization of pathogens. Therefore, understanding the molecular and cellular mechanisms regulating plasma cell differentiation and function is important in designing vaccines to generate better humoral responses and approaches to target harmful plasma cells.
Differentiation of B cells into plasma cells is regulated by the coordinated expression and repression of multiple transcription factors. The transcription factors Pax5, Bcl-6, and Bach2 are expressed in B cells, support the transcriptional program that maintains B cell identity, and suppress plasma cell differentiation [3] [4] [5] [6] [7] . On the other hand, the transcriptional programs induced by BLIMP1, IRF4, and XBP1 extinguish B cell genes and stimulate differentiation of plasma cells [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Other transcription factors such as IRF8 and PU.1 negatively regulate plasma cell differentiation by stimulating expression of Bcl-6 and Pax5 19 . Similarly, microphthalmia-associated transcription factor inhibits plasma cell development by suppressing IRF4 and BLIMP1 20 . In general, plasma cell-associated transcription factors oppose the function of the transcription factors responsible for maintaining B cell identity and vice versa.
Accumulation of unfolded proteins in the endoplasmic reticulum (ER) lumen results in ER stress. Cells respond to ER stress via activation of unfolded protein response (UPR) pathway. Three UPR pathways: inositol-requiring transmembrane kinase/endonuclease 1 (IRE1), PKR-like ER protein kinase (PERK), and activating transcription factor 6 (ATF6) sense the ER stress, induce signaling to upregulate expression of chaperones, and expand ER network leading to enhancement of protein folding capacity of ER. The expanded ER network facilitates proper folding and secretion of a large amount of secretory proteins. Thus, UPR pathway plays a central role in development and function of secretory cells. Plasma cells are secretory cells. Liganddriven model suggests that during ER stress, interaction of ER luminal domains of IRE1α and PERK with misfolded proteins plays an important role in their activation 21, 22 . Since ER luminal domains of PERK and IRE1α share similar conserved residue and mutational analysis suggest similar requirements for their activation, it is surprising that during development of plasma cells, IRE1α is robustly activated, whereas activation of PERK is suppressed 16, [23] [24] [25] [26] . The mechanism and significance of PERK suppression in developing plasma cells are not fully understood.
The endonuclease activity of IRE1α excises a 26-nucleotide segment from the XBP1 mRNA. The splicing shifts the reading frame, resulting in the translation of full-length XBP1, which translocates into the nucleus and transcribes genes involved in ER expansion, protein folding, protein synthesis, and transcription of secretory IgM in plasma cells 13, 16, [27] [28] [29] . In the absence of XBP1, plasma cells develop normally but due to defective expansion of ER network and Igh mRNA processing, show impaired ability to secrete immunoglobulins 8, 25, 30 . However, identity of XBP1 target/(s) that play a pivotal role in the expansion of ER in plasma cells remains poorly characterized.
Ubiquitin-fold modifier 1 (Ufm1) is a ubiquitin-like polypeptide that is post-translationally conjugated to target proteins via the ufmylation process and thereby modifies their function. Similar to ubiquitinylation, ufmylation is a three-step biochemical reaction catalyzed by specific E1 (Uba5), E2 (Ufc1), and E3 (Ufl1) [31] [32] [33] . Ufm1-binding protein (Ufbp1, DDGRK1, C20orf116, or Dashurin) is the first identified target of the Ufm1 pathway 33, 34 . Anomalies in the ufmylation pathway are associated with neuronal diseases [35] [36] [37] [38] [39] , spondyloepiphyseal dysplasias 40 , developmental defects 41 , and blood disorders 42, 43 . We and others have recently published that Uba5, Ufl1, and Ufbp1 play a key role in the survival of hematopoietic stem cells and hematopoiesis [44] [45] [46] . Ufmylation pathway is upregulated following pharmacological ER stress and protects cells under these conditions 34, 47 . Nonetheless, it is unknown whether Ufbp1 is a general regulator of all three branches of UPR pathway or plays different roles at different branches of UPR pathway.
In this study, we show that Ufbp1-mediated suppression of PERK has an essential function in the differentiation of naive B cells into plasma cells. In addition, Ufbp1 is upregulated downstream of IRE1α /XBP1 pathway to critically enforce the expansion of ER network and function of plasma cells.
Results
Ufbp1 regulates humoral immune responses. To study the role of Ufbp1 in the biology of B cells and plasma cells, we crossed Ufbp1 flox/flox (Ufbp1 F/F ) mice with CD19 cre/+ (CD19 cre ) mice and obtained Ufbp1 F/F CD19 cre mice. Ufbp1 F/F CD19 cre mice were born and remain healthy for rest of their life. B cells (B220 + CD19 + cells) were present at comparable frequencies and numbers in the spleen and lymph nodes of Ufbp1 F/F CD19 cre and Ufbp1 F/F mice ( Fig. 1a , Supplementary Fig. 1a-d ). Expression levels of CD19 and B220 were also comparable between these two lines of mice. Frequencies of IgM low IgD high , IgM high IgD low , and IgM high IgD high cells were also similar between Ufbp1 F/F CD19 cre and Ufbp1 F/F mice ( Supplementary Fig. 1e ). Naive B cells from Ufbp1 F/F mice expressed low levels of Ufbp1 protein, which was upregulated~10fold following lipopolysaccharide (LPS) treatment ( Supplementary  Fig. 1f ). In contrast, Ufbp1 protein expression in naive B cells and LPS-activated B cells from Ufbp1 F/F CD19 cre mice was~5-and 17-fold lower respectively than Ufbp1 F/F mice, indicating efficient deletion of Ufbp1 in the B cells of the former ( Supplementary  Fig. 1f ). Notwithstanding, with normal number of B cells, serum immunoglobulins of all isotypes were present at significantly lower levels in unimmunized Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice ( Fig. 1b) . To test the role of Ufbp1 expression in B cells in T-celldependent (TD) antibody responses, 4-hydroxy-3nitrophenylacetyl (NP) conjugated to keyhole limpet hemocyanin (KLH; NP-KLH) precipitated on alum was injected intraperitoneally (i.p.) into Ufbp1 F/F CD19 cre and Ufbp1 F/F mice. At all the time points following immunization (days 7, 21, and 90) compared to Ufbp1 F/F mice, Ufbp1 F/F CD19 cre mice exhibited significantly lower serum levels of NP-specific antibodies of the isotypes, IgM, IgG1, and IgG3 ( Fig. 1c ). NP-specific antibodies of IgG2a and IgG2b were also present at significantly reduced level on day 21 and 90 in sera of Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice. In addition, following immunization with T-cell-independent (TI) antigen, NP-ficoll, Ufbp1 F/F CD19 cre mice also generated significantly reduced quantities of NP-specific antibody of the IgG3 isotype than Ufbp1 F/F mice ( Fig. 1d ). Taken together, these data show that Ufbp1 expression in B cells is necessary for the generation of TD as well as TI antibody responses.
Defective generation of plasma cells in Ufbp1 F/F CD19 cre mice. Due to the significant reduction in both serum immunoglobulins and antibody responses, the number of plasma cells was evaluated in Ufbp1 F/F CD19 cre mice. First, sorted splenic naive B cells (B220 + CD138 − ) and bone marrow plasma cells (B220 − CD138 high ) from wild-type (WT) mice were compared for expression of Ufbp1 and the genes involved in ufmylation pathway: Uba5, Ufc1, Ufl1, and Ufm1 by quantitative real-time PCR (qRT-PCR). These genes were expressed at a significantly higher level in plasma cells than naive B cells ( Supplementary Fig. 2a ). Bone marrow and spleens of Ufbp1 F/F CD19 cre mice contained significantly reduced frequency of plasma cells (BLIMP1 + CD138 high and IRF4 + Pax5 − ) than Ufbp1 F/F mice ( Fig. 2a, b , Supplementary  Fig. 2b , c). We also evaluated the frequency and number of plasma cells after immunization with NP-KLH. Following immunization, plasma cells were still present at a significantly lower frequency in bone marrow and spleens of Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice at all the time points evaluated (Fig. 2c, d , Supplementary Fig. 2d, e ). ELISpot assay confirmed significantly lower numbers of ASCs in the bone marrow and spleens of Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice ( Fig. 2e , f, Supplementary Fig. 2f , g). To analyze the development of antigenspecific plasma cells in vivo, mice were immunized with NP-KLP in the Sigma Adjuvant System (Monophosphoryl Lipid A-based adjuvant). One week later, 7-AAD − CD4 − CD8 − Gr-1 − CD11b − cells were analyzed for binding to NP and plasma cells. Similar fractions of IgD − cells showed binding to NP in the spleens of Ufbp1 F/F CD19 cre and Ufbp1 F/F mice, suggesting that clonal expansion of B cells following antigen encounter is unaffected by deficiency of Ufbp1 ( Fig. 2g, h ). However, significantly lower frequency of plasma cells (BLIMP1 + CD138 high and BLIMP1 + ) among NP-specific cells was present in Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice ( Fig. 2i, j) . Collectively, these data demonstrate that Ufbp1 is dispensable for the expansion of B cells but plays an essential role in the differentiation of antigen-activated B cells into plasma cells.
Differentiation of B cells into plasmablast depends on Ufbp1.
Naive B cells activated in vitro with LPS, interleukin (IL)-4, and IL-5 differentiate into plasmablasts. Like plasma cells, plasmablasts are ASCs, positive for CD138, BLIMP1, IRF4, negative for Pax5, and possess a highly developed ER network. In addition, the same set of transcription factors drive the development of plasmablasts and plasma cells 48 Presence of indicated immunoglobulin isotypes in the serum of indicated mice was quantified using enzyme-linked immunosorbent assay (ELISA) (n = 4 mice/genotype). c Six-week-old Ufbp1 F/F and Ufbp1 F/F CD19 cre mice were immunized with 4-hydroxy-3-nitrophenylacetyl conjugated to keyhole limpet hemocyanin (NP-KLH; 100 µg/mouse, intraperitoneally) in alum. NP-specific antibodies of IgM, IgG1, IgG2a, IgG2b, and IgG3 isotypes in the sera of the mice at indicated time points after immunization were quantified using ELISA (n = 5 mice/genotype). Samples were normalized against day 14 sera obtained from wild-type mice immunized with NP-KLH. d Ufbp1 F/F and Ufbp1 F/ F CD19 cre mice were immunized with NP-Ficoll (25 µg/mouse) intraperitoneally in phosphate-buffered saline. NP-specific antibody of IgG3 isotype in the mice were cultured with LPS, IL-4, and IL-5. Four days later, the development of plasmablasts (BLIMP1 + CD138 high and IRF4 + Pax5 − ) was analyzed in these cultures. Plasmablasts were present at significantly reduced frequency in the cultures started with B cells from Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice ( Fig. 3a-d) . Similarly, frequencies of single positive BLIMP1 + and IRF4 + cells were also significantly reduced in cultures started with B cells from Ufbp1 F/F CD19 cre than Ufbp1 F/F mice ( Supplementary Fig. 3a, b) . Accordingly, the levels of secreted IgM were significantly decreased in the 
Decreased number of plasma cells in Ufbp1 F/F CD19 cre mice. a Bone marrow cells from indicated mice were stained with BLIMP1, CD138, IRF4, and Pax5, and analyzed by flow cytometry. Shown is the BLIMP1 versus CD138 (upper panel), and IRF4 versus Pax5 staining (lower panel) b Enumeration of frequencies of BLIMP1 + CD138 + and IRF4 + Pax5 − cells in a (n = 3 mice/genotype). c Ufbp1 F/F and Ufbp1 F/F CD19 cre mice immunized with 4-hydroxy-3-nitrophenylacetyl conjugated to keyhole limpet hemocyanin (NP-KLH) as in Fig. 1c were analyzed for plasma cells (BLIMP1 + CD138 + and IRF4 + Pax5 − ) in bone marrow by flow cytometry at the indicated time points after immunization. d Enumeration of the frequencies of plasma cells (BLIMP1 + CD138 + and IRF4 + Pax5 − ) in c (n = 3 mice/genotype). e Indicated mice were immunized as in Fig. 1c . Twenty-one days later, bone marrow cells were analyzed for the presence of NP-specific IgG1 + ASCs by ELISpot. Shown is a photograph of representative ELISpot wells. f Number (mean ± SEM) of NP-specific IgG1 + ELISpots in e (n = 6 mice/ genotype). g Ufbp1 F/F and Ufbp1 F/F CD19 cre mice were immunized with NP-KLH in Sigma Adjuvant System and on day 10, 7- Supplementary Fig. 3c ). Most importantly, LPS-, IL-4-, and IL-5-induced defective development of Ufbp1deficient B cells into plasmablasts was rescued by exogenous expression of Ufbp1, suggesting that Ufbp1 deficiency in B cells did not cause an irreversible defect in their ability to differentiate into plasmablasts ( Fig. 3e , f, Supplementary Fig. 3d) . Surprisingly, Ufbp1K267R, a mutant of Ufbp1 in which lysine at position 267 was changed to arginine and thus does not undergo ufmylation, promoted plasma cell development comparable to WT Ufbp1 (Fig. 3e , f, Supplementary Fig. 3d ) 33 .
Since lysine 267 (K267) is the main lysine in Ufbp1 that undergoes ufmylation, these data suggest that Ufbp1 promotes plasma cell development independent of its ufmylation at lysine 267. However, we cannot rule out the role of ufmylation of other conserved lysines at positions 116, 121, 124, 128, 193, 224, and 227 of Ufbp1 in development of plasma cells. Alternatively, it is possible that Ufbp1 promotes plasma cell development independent of its ufmylation. WT Ufbp1 significantly rescued immunoglobulin production by Ufbp1-deficient plasmablasts, whereas Ufbp1K267R failed to do so (Supplementary Fig. 3e ). Therefore, lysine 267 of Ufbp1 distinguishes between its role in plasma cell development versus immunoglobulin production. Collectively, these data demonstrate an essential role of Ufbp1 in the differentiation of B cells into plasmablasts.
Ufbp1 expands ER in plasma cells. To gain insight into the mechanism of Ufbp1-mediated regulation of plasma cell biology, we first analyzed the subcellular distribution of Ufbp1. Cell lysates from LPS-activated B cells were fractionated into cytosol and ER fractions and analyzed for Ufbp1. Figure 4a shows that Ufbp1 is exclusively present in the ER fraction. Immunocytochemistry staining confirmed co-localization of Ufbp1 with ER marker protein disulfide isomerase (PDI) (Fig. 4b ). Due to Ufbp1 localization on the ER and a critical role for the ER in the functional biology of plasma cells, we analyzed the ER network in plasmablasts lacking Ufbp1. First, we determined the total ER mass in CD138 − and CD138 + cells from LPS-stimulated B cell cultures by an ER-tracker dye. On day 1 and 2 of LPS stimulation, Ufbp1sufficient and -deficient B cells showed similar levels of ER staining ( Supplementary Fig. 4a-d) . On day 3 of LPS culture, both CD138 − and CD138 + cells are present in cultures. Ufbp1sufficient and -deficient CD138 − cells exhibited comparable staining with the ER-tracker ( Fig. 4c, d) . In contrast, Ufbp1deficient CD138 + cells showed significantly reduced staining for ER-tracker than their Ufbp1-sufficient counterparts, suggesting a lower ER mass in the former (Fig. 4c, d) . Similarly, Ufbp1deficient plasmablasts (CD138 high TACI + ) induced by LPS, IL-4, and IL-5 exhibited significantly decreased staining for ER-tracker dye than Ufbp1-sufficient counterparts ( Supplementary Fig. 4e ). We used transmission electron microscope (TEM) to analyze the ER network in Ufbp1-sufficient and -deficient CD138 + cells. Ufbp1-sufficient CD138 + cells displayed a well-developed ER network and most of the intracellular space was occupied by the ER, a characteristic of plasma cells (Fig. 4e) . In sharp contrast, most of the intracellular space was devoid of the ER network in Ufbp1-deficient CD138 + cells (Fig. 4e ). Consistent with these findings and most importantly, TEM studies confirmed the absence of a well-developed ER network in bone marrow plasma cells from Ufbp1 F/F CD19 cre mice, whereas the intracellular space of bone marrow plasma cells from Ufbp1 F/F mice was filled with ER ( Fig. 4f ). We also evaluated ER-tracker staining on plasma cells from spleen and bone marrow. CD138 is not a reliable marker for identification for plasma cells in vivo. Fixation and permeabilization procedures used for staining of transcription factors associated with plasma cell identification may interfere with ER-tracker staining. Using BLIMP1-GFP mice, several groups have shown that CD138 in combination with TACI, Sca-1, or CD98 accurately identifies plasma cells in spleen and bone marrow [49] [50] [51] . Therefore, CD138 high TACI + cells (plasma cells) in bone marrow and spleens were analyzed for ER-tracker staining. Staining for the ER-tracker was significantly lower in plasma cells (CD138 high TACI + ) from the bone marrow and spleens of Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice ( Supplementary  Fig. 4f ). Collectively, these data indicate that Ufbp1 plays an essential role in the expansion of the ER network in ASCs.
Ufbp1 regulates IRE1α and PERK branches of UPR pathway. XBP1 is a master transcription factor that plays an indispensable role in the ER expansion in plasma cells 16, 25 . Due to the absence of a well-developed ER network in Ufbp1-deficient plasmablasts and plasma cells, the expression of XBP1 was analyzed. Surprisingly, XBP1 staining was significantly higher in bone marrow plasma cells from Ufbp1 F/F CD19 cre mice than Ufbp1 F/F mice (Fig. 5a, b) . Similarly, CD138 − and CD138 + cells from LPSstimulated B cell cultures from Ufbp1 F/F CD19 cre mice showed significantly brighter staining for XBP1 than their counterparts from Ufbp1 F/F mice ( Supplementary Fig. 5a, b) . It is unlikely that impaired transcriptional activity of XBP1 in Ufbp1-deficient plasma cells is the underlying mechanism for defective ER expansion, because the XBP1 target genes EDEM1, ERDJ4, PDI, and Sec61a were expressed at comparable levels in Ufbp1sufficient and -deficient plasma cells ( Supplementary Fig. 5c ). Similarly, Ufbp1 deficiency did not affect the expression of Sec61a, PDI, and EDEM1 in CD138 − and CD138 + cells from LPS-stimulated cultures ( Supplementary Fig. 5d ). Induction of the UPR during development of plasma cells leads to activation of IRE1α. IRE1α-mediated splicing and subsequent activation of the transcription factor XBP1 plays an essential and indispensable role in the expansion of ER network 16, 52 . Therefore, the role of Ufbp1 in regulation of UPR signaling was analyzed. Naive B cells from Ufbp1 F/F and Ufbp1 F/F CD19 cre mice were activated with LPS and on day 0,1, 2, and 3 whole-cell lysates were immunoblotted with antibodies against molecules involved in UPR signaling. Expression of IRE1α protein increased in both Ufbp1-sufficient and -deficient LPS-activated B cells from day 0 to day 3 (Fig. 5c,  d) . Using short hairpin RNA-mediated knockdown of Ufbp1, a recent article shows that IRE1α is degraded in the absence of Ufbp1 53 . In contrast, we found that Ufbp1-deficient LPS-activated B cells expressed higher amount of total IRE1α protein than their Ufbp1-sufficient counterparts (Fig. 5c, d) . Consistent with this, higher amount of spliced XBP1 mRNA and protein was present in Ufbp1-deficient than Ufbp1-sufficient LPS-activated B cells on day 1, 2, and 3 ( Fig. 5c, d, Supplementary Fig. 5e, f) . Similarly, Ufbp1 deficiency resulted in higher splicing of XBP1 in CD138 − and CD138 + cells from LPS-stimulated cultures and bone marrow plasma cells ( Supplementary Fig. 5g, h) . When expression of IRE1α and XBP1 was compared on day 1 and 2 between Ufbp1-sufficient and -deficient B cells, fold increase in expression of XBP1 in later correlated with higher expression of IRE1α in them ( Fig. 5e ), suggesting that at single-molecule level, Ufbp1 deficiency does not change the activity of IRE1α. Collectively, these data demonstrate that during B cell activation, absence of Ufbp1 leads to upregulation of IRE1α expression.
In addition to IRE1α activation, UPR also induces activation of PERK. The PERK branch of UPR is specifically suppressed in activated B cells 24, 54 . On day 1 of LPS stimulation, phosphorylated form of PERK (p-PERK) was increased by~>5-fold in Ufbp1deficient B cells than Ufbp1-sufficient cells ( Fig. 5f-h) . A similar trend for phosphorylated form of eIF2α (p-eIF2α) was also observed ( Fig. 5f-h) . Consistent with this, protein level of ATF4 was increased by~10-fold in Ufbp1-deficient than Ufbp1-sufficient B cells on day 1 (Fig. 5f-h ). No noticeable difference in phosphorylation of PERK and eIF2α between Ufbp1-sufficient and -deficient B cells was observed on day 2 and 3. However, ATF4 was still expressed at higher level on day 2 and 3 in Ufbp1-deficient B cells, although the fold increase compared with Ufbp1-sufficient B cells was of lesser extent than on day 1. Activation of PERK during ER stress may lead to apoptosis 55 . Similar numbers of live cells were recovered at all the time points (day 1, 2, and 3) in cultures containing B cells from Ufbp1 F/F and Ufbp1 F/F CD19 cre mice ( Supplementary Fig. 5i ). Annexin-V and 7-AAD staining showed comparable survival of Ufbp1-sufficient and -deficient B cells in these cultures (Supplementary Fig. 5j ). Taken together, these data suggest that Ufbp1 is a negative regulator of PERK activation.
Ufbp1 promotes plasma cell development by suppressing PERK. Next, we tested whether Ufbp1 deficiency-induced activation of PERK inhibits differentiation of Ufbp1-deficient B cells into plasma cells. To test this hypothesis, we generated mice lacking Ufbp1 and PERK in B cells, Perk F/F Ufbp1 F/F CD19 cre . B cells from WT, Perk F/F CD19 cre , Ufbp1 F/F CD19 cre , and Perk F/F Ufbp1 F/F CD19 cre mice were cultured with LPS and expression of ATF4 was analyzed as a marker of PERK activation. Deletion of PERK reduced the expression of ATF4 in the Ufbp1-deficient B cells to the levels observed in WT B cells ( Supplementary Fig. 6a ). Additionally, ATF4 level in WT B cells was comparable to that seen in PERK-deficient B cells. Next bone marrow and spleens of WT, Perk F/F CD19 cre , Ufbp1 F/F CD19 cre , and Perk F/F Ufbp1 F/F CD19 cre mice were analyzed for plasma cells. Frequencies of plasma cells (BLIMP1 + CD138 high ) in the spleens and bone marrow of WT, Perk F/F CD19 cre , and Perk F/ F Ufbp1 F/F CD19 cre mice were similar to each other and significantly higher than in Ufbp1 F/F CD19 cre mice ( Fig. 6a-d) . These data suggested that deletion of PERK rescued development of Ufbp1deficient B cells into plasma cells. To test this premise, B cells from WT, Perk F/F CD19 cre , Ufbp1 F/F CD19 cre , and Perk F/F Ufbp1 F/F CD19 cre mice were cultured with LPS, IL-4, and IL-5, and their differentiation into plasmablasts was analyzed. Similar number of live cells were recovered in all the culture at all the time points, suggesting that deletion of PERK or Ufbp1 does not affect the survival or proliferation of B cells ( Supplementary Fig. 6c ). On day 4, comparable frequency of plasmablasts (BLIMP1 + CD138 high and IRF4 + Pax5 − cells) developed in cultures of WT and PERK-deficient B cells, which was significantly higher than in cultures of Ufbp1-deficient B cells (Fig. 6e, f, Supplementary Fig. 6d (Fig. 6e, f, Supplementary Fig. 6d ). Taken together, these data demonstrate that Ufbp1 promotes plasma cell development by suppressing PERK activation.
We also tested whether deletion of PERK restores the defective ER expansion in Ufbp1-deficient plasma cells and plasmablasts. Spleen and bone marrow plasma cells lacking either Ufbp1 or both Ufbp1 and PERK showed significantly decreased staining for ERtracker than their WT or PERK-deficient counterparts (Fig. 6g, h,  Supplementary Fig. 6b ). Similarly, WT and PERK-deficient plasmablasts (CD138 high TACI + cells) induced by LPS, IL-4, and IL-5 showed significantly higher staining for ER-tracker than those lacking either Ufbp1 or both Ufbp1 and PERK (Supplementary NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08908-5 ARTICLE Fig. 6e ). Consistent with this, TEM images confirmed absence of a well-developed ER network in plasmablasts from LPS-stimulated B cell cultures from Ufbp1 F/F CD19 cre and Perk F/F Ufbp1 F/F CD19 cre mice (Fig. 6i ). On the other hand, plasmablasts from LPSstimulated B cell cultures from both WT and Perk F/F CD19 cre mice possessed a highly developed ER network (Fig. 6i) . A welldeveloped ER network plays an important role in immunoglobulin secretion by plasma cells. Therefore, immunoglobulin secretion by plasma cells and plasmablasts from WT, Perk F/F CD19 cre , Ufbp1 F/ F CD19 cre , and Perk F/F Ufbp1 F/F CD19 cre mice were analyzed. Bone marrow plasma cells and plasmablasts from Ufbp1 F/F CD19 cre and Perk F/F Ufbp1 F/F CD19 cre mice produced significantly less IgM antibody than their counterparts from WT and Perk F/F CD19 cre mice (Fig. 6j, k) . ELISpot assay also showed significantly decreased number of ASCs in plasmablasts from Ufbp1 F/F CD19 cre and Perk F/ F Ufbp1 F/F CD19 cre mice than WT and Perk F/F CD19 cre mice (Fig. 6l , Supplementary Fig. 6f ). Accordingly, and notwithstanding with normal numbers of plasma cells in bone marrow and spleen, Perk F/ F Ufbp1 F/F CD19 cre mice exhibited significantly reduced levels of all the immunoglobulin isotypes in their sera than WT and Perk F/ F CD19 cre ( Supplementary Fig. 6g ). Collectively, these data demonstrate that Ufbp1 promotes plasma cell development via suppressing PERK branch of UPR but stimulates ER homeostasis and plasma cell function in a PERK-independent manner.
Ufbp1 downstream to XBP1 expands the ER network. Notwithstanding with the higher expression of XBP1, Ufbp1-deficient plasma cells and plasmablasts show a defective ER expansion. Therefore, we hypothesized that Ufbp1 and the ufmylation system are induced by the IRE1α/XBP1 axis in plasma cells and plasmablasts. Ire1α F/F and Ire1α F/F CD19 cre mice were utilized to address this hypothesis. Expression of Ire1α mRNA was drastically reduced in naive B cells and bone marrow plasma cells of Ire1α F/F CD19 cre mice than Ire1α F/F mice suggesting efficient deletion of Ire1α gene in the former mice (Fig. 7a ). We found that expression of Ufbp1 as well all the molecules involved in ufmylation pathway Uba5, Ufc1, Ufl1, and Ufm1 was significantly lower in bone marrow plasma cells from Ire1α F/F CD19 cre mice than Ire1α F/F mice (Fig. 7a) . The deficiency was specific to the plasma cells, because IRE1α-sufficient and -deficient naive B cells express comparable levels of Ufbp1, Uba5, Ufc1, Ufl1, and Ufm1 (Fig. 7a, b, Supplementary Fig. 7a ). LPS, a known inducer of differentiation of naive B cells into plasmablasts, significantly upregulated the expression of Ufbp1, Uba5, Ufc1, Ufl1, and Ufm1 in WT B cells ( Fig. 7b, Supplementary Fig. 7a ). In contrast, under similar conditions, LPS failed to upregulate Ufbp1, Uba5, Ufc1, Ufl1, and Ufm1 in IRE1α-deficient B cells (Fig. 7b , Supplementary Fig. 7a ). At protein level, expression of~48%, 34%, 52%, 43%, and 60% Ufbp1, Uba5, Ufc1, Ufl1, and Ufm1 respectively is IRE1α/XBP1-independent in LPS-activated B cells (Supplementary Fig. 7a ). A similar data were observed when the expression of Ufbp1, Uba5, Ufc1, Ufl1, and Ufm1 was compared between IRE1α-sufficient and -deficient CD138 − and CD138 + cells sorted from LPS-stimulated B-cell cultures (Fig. 7c ). Whole-cell lysates from LPS-activated B cells from WT, Ire1α F/F CD19 cre , and Ufbp1 F/F CD19 cre mice were immunoblotted with anti-Ufm1 antibody to gain insight into ufmylation activity of these cells. Several ufmylated bands were present at lower levels in LPSactivated B cells from Ire1α F/F CD19 cre mice than WT B cells ( Supplementary Fig. 7b ). Interestingly, intensity of ufmylated bands of approximate molecular weight of 30 and 35 kDa was reduced in IRE1α-deficient B cells, whereas intensity of 30 kDa band was unchanged and of 35kDa was increased in Ufbp1deficient B cells than WT counterparts ( Supplementary Fig. 7b ). This is not surprising because in Ufbp1-deficient B cells either ufmylation events downstream to Ufbp1 are expected to be reduced and/or in the absence of Ufbp1, ufmylation of Ufbp1independent targets may go up. In contrast, due to decreased expression of all the molecules involved in ufmylation pathway, ufmylation of all the targets are estimated to go down in IRE1αdeficient B cells. Consistent with the essential role of IRE1 in the activation of transcription factor XBP1, LPS-activated B cells from Ire1α F/F mice expressed transcription factor XBP1, whereas XBP1 expression was undetectable in LPS-activated B cells from Ire1α F/F CD19 cre mice (Fig. 7b ). Next, LPS-stimulated WT and IRE1α-deficient B cell cultures were transduced with retroviruses expressing empty vector or unspliced or spliced XBP1. Figure 7d and Supplementary Fig. 7c show that ectopic expression of spliced XBP1 (XBP1s) but not unspliced XBP1 (XBP1u) in IRE1α-deficient CD138 + cells from LPS-stimulated cultures significantly upregulated the expression of Ufbp1, Uba5, Ufc1, Ufl1, and Ufm1. These findings suggest that Uba5, Ufc1, Ufl1, Ufbp1, and Ufm1 are expressed in plasma cells and LPS-activated B cells in both IRE1α/XBP1-dependent and -independent manner. Upregulation of all the components of Ufm1 system: Uba5, Ufc1, Ufl1, and Ufm1 along with Ufbp1 by IRE1α/XBP1 and defective ER expansion in CD138 + cells lacking IRE1α, XBP1, or Ufbp1 suggest that ufmylation of Ufbp1 may play an important role in ER expansion. To test this hypothesis, IRE1α-deficient B cells were activated with LPS, IL-4, and IL-5 and transduced with retroviruses expressing empty vector and Ufbp1. As expected from previous studies, IRE1α-deficient plasmablasts from empty retrovirus-infected cells showed significantly reduced staining for ER-tracker than WT counterpart, suggesting decreased ER mass in former (Fig. 7e ). Overexpression of Ufbp1 partially but significantly rescued the ER mass in IRE1α-deficient plasmablasts (Fig. 7e) . The partial expansion of ER in Ufbp1-expressing IRE1α-deficient plasmablasts may undermine the role of Ufbp1 in ER expansion because all the enzymes required for ufmylation of Ufbp1 are expressed at much lower level in these cells (Fig. 7b, c) , which may result in under-ufmylation of Ufbp1. Consistent with this, Ufbp1K267R expression did not significantly change the ER staining in IRE1α-deficient plasmablasts. Since ER Fig. 6 Ufbp1 promotes development of plasma cells by suppressing PKR-like ER protein kinase (PERK). a, b BLIMP1 and CD138 expression by splenocytes (a) and bone marrow cells (b) from indicated mice was analyzed by flow cytometry (n = 3 mice/genotype). c, d Enumeration of frequency of plasma cells (BLIMP1 + CD138 high ) in a and b respectively (n = 3 mice/genotype). e Naive B cells from indicated mice were stimulated with lipopolysaccharide (LPS), interleukin (IL)-4, and IL-5 as in Fig. 3a . Four days later expression of BLIMP1 and CD138 was analyzed by flow cytometry. f Enumeration of frequency of BLIMP1 + CD138 high cells in e (n = 3 mice/genotype). g ER-tracker staining of splenic plasma cells (CD138 + TACI + cells) from indicated mice. h Quantification of ER-tracker staining of plasma cells in g (n = 3 mice/genotype). i Transmission electron microscope images of CD138 + cells sorted from LPS-stimulated B cell cultures from indicated mice. Scale bars are 1 µm. j CD138 + cells (10 4 cells/well) sorted from LPS-stimulated B cell cultures from indicated mice were cultured for 4 h and IgM production in culture supernatants was analyzed by enzyme-linked immunosorbent assay (ELISA). k Bone marrow plasma cells (4 × 10 3 cells/well) from indicated mice were cultured overnight and IgM production in culture supernatants was analyzed by ELISA. l Enumeration of antibody-secreting cells by ELISpot in CD138 + population sorted from LPS-stimulated B cell cultures from indicated mice. Error bars represent mean ± standard error. **P < 0.01, ***P < 0.001. Unpaired Student's two-tailed t-test was used. A representative of two experiments is shown expansion plays a critical role in immunoglobulin production 16, 25, 56 , inability of Ufbp1K267 to expand ER is consistent with its failure to enhance production of IgM by Ufbp1deficient plasmablasts in Supplementary Fig. 3e . The partial rescue of ER mass in Ufbp1-expressing IRE1α-deficient plasmablasts may also be due to lower expression of other XBP1 targets (such as PDI, EDEM1, ERDj4, Sec61a, etc) involved in ER expansion. Taken together, these data suggest that although expression of Ufbp1 and components of ufmylation system in naive B cells are IRE1α/XBP1-independent, their upregulation downstream of IRE1α/XBP1 plays a critical role in ER expansion in plasma cells and plasmablasts.
Discussion
In this report, we show that Ufbp1, a target and co-factor of the Ufm1 system plays an essential role in the development of plasma cells and expansion of the ER network. Previous studies have ARTICLE reported specific suppression of PERK pathway in developing plasma cells 23, 24 . Our study shows that Ufbp1 plays an essential role in suppression of PERK pathway. The relevance of this suppression is evident from the finding that deletion of PERK restored the defective development of Ufbp1-deficient B cells into plasma cells. Expression of Ufbp1 and other molecules involved in ufmylation pathway in naive B cells is independent of IRE1α/ XBP1. In contrast, in plasma cells, expression of a significant fraction of Ufbp1 downstream to IRE1α/XBP1 performs a critical function in expansion of ER network. Thus, differential involvement of Ufbp1 in regulation of different steps of UPR pathway has distinct outcomes on the development and function of plasma cells.
Skin fibroblasts from individuals with biallelic mutations in Uba5, one coding for a truncated protein and the other coding for a loss of function resulting in a defective ufmylation pathway, are resistant to tunicamycin-induced toxicity and show an expanded ER network 35 . In contrast, our findings show that Ufbp1 deficiency leads to impaired expansion of the ER network. Although it is possible that the ufmylation pathway may differentially affect the ER network in different cell types, the opposing effects may also be explained by the fact that the loss of Uba5 function is expected to result in no-ufmylation of all the targets, whereas Ufbp1 deficiency will only affect the ufmylation of molecule(s) downstream to it. Therefore, a better understanding of the ufmylation pathway and its targets are needed to understand the importance of this pathway in the regulation of ER homeostasis in plasma and other secretory cells.
In contrast to numerous studies focusing on transcriptional regulation of gene expression, only a handful of studies have aimed to address the control of mRNA translation in regulating cellular differentiation and function. mTOR signaling regulates translation of mRNA involved in the biology of prostate cancer proliferation, metabolism, and invasion 57 . Ribosome profiling has demonstrated how translational control of mRNA regulates cell cycle 58, 59 . Ribosome-associated protein RPL38 plays a key role in the translation of a selected set of homeobox mRNAs and thereby regulates tissue patterning 60 . A recent article showed that Ufl1 is part of the ribosome and ufmylates ribosome-associated proteins uS3, uS10, uL16, and eIF6 61 . Given the strong association between Ufl1 and Ufbp1 33, 44 , it is possible that the Ufl1/Ufbp1 complex is part of the ribosomes and regulate their composition and/or function on the ER. Future studies are necessary to test (1) whether Ufl1/Ufbp1 complex regulates translational control during plasma cell development, and (2) if so, its relevance to the biology of plasma cells.
The current study also shows that Ufbp1 regulates development of plasma cells by suppression of PERK pathway. Accumulation of ATF4 is the first stable product of the activation of PERK pathway. Higher level of ATF4 was present in LPSactivated Ufbp1-deficient B cells than WT B cells. In contrast, ATF4 level between WT, PERK-deficient, and PERK/Ufbp1 double-deficient B cells was comparable. These findings suggest that Ufbp1 completely suppresses PERK activation during development of plasma cells and may explain the previous findings showing no abnormality in development of plasma cells in mice lacking PERK. How does Ufbp1 suppress activation of PERK? A recent article shows that Ufbp1 is required for stability of IRE1α and thus depletion of Ufbp1 results in diminished IRE1α/XBP1 signaling leading to disturbed ER homeostasis and activation of PERK 53 . However, higher expression and activation of IRE1α/XBP1 in Ufbp1-deficient B cells argues against this possibility. Alternatively, it is possible that Ufbp1 represses PERK activity by directly interacting with it or indirectly by influencing some critical step in ER homeostasis. PERK is known to regulate survival, self-renewal, proliferation, and differentiation of different cell types such as osteoblasts, skeletal muscle, adipocytes, neonatal pancreatic β-cells, and hematopoietic stem cells [62] [63] [64] [65] . Its effect on proliferation and differentiation of insulin-secreting βcells of endocrine pancreas during fetal and neonatal development is unrelated to ER stress and UPR pathway 63 . Additionally, PERK promotes adipocyte differentiation via intrinsic lipid kinase activity 66 . Therefore, the possibility arises that PERK may suppress the differentiation of naive B cells into plasma cells via pathway not related to ER stress or UPR pathway. In summary, the current study shows an unprecedented role for Ufbp1 and the ufmylation pathway in the development and function of plasma cells by differentially affecting the different steps of UPR pathway and thus suggests that manipulation of ufmylation pathway may have therapeutic potential for the treatment of plasma cell-related pathologies.
Methods
Mice. Ufbp1 F/F mice and Ire1α F/F mice were previously described 44, 67 . C57BL/6J, Perk F/F , and CD19 Cre mice were purchased from The Jackson Laboratory. Ufbp1 F/F , Perk F/F , and Ire1α F/F mice were crossed with CD19 Cre mice to obtain Ufbp1 F/ F CD19 cre , Perk F/F CD19 cre and Ire1α F/F CD19 cre mice respectively. Ufbp1 F/F CD19 cre and Perk F/F mice were used to generate Perk F/F Ufbp1 F/F CD19 cre mice. The following PCR primers were used for genotyping of the indicated mice: Ufbp1 F/F (5′-TAGTACTTGAAGTCTGGCTTGGTA-3′ and 5′-TAGTCAGGAACTGATG AGTGTCTC-3′), Ire1α F/F (5′-CAGAGATGCTGAGTGAAGAC-3′ and 5′-ACA GTGGTTCCTGTGAAGGT-3′), CD19 Cre (5′-GTGAAACAGCATTGCTGTCACT T-3′, 5′-TGGTCTGAGACATTGACAATCA-3′, and 5′-CTGGCTACCATGCCAT CTCC-3′), and Perk F/F (5′-TTGCACTCTGGCTTTCACTC-3′ and 5′-AGGAGGA AGGTGGAATTTGG-3′). The Institutional Animal Care and Use Committee, Augusta University approved all the animal procedures. Mice of both sexes between 6 and 24 weeks of age were randomly used.
